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Background
Collaborative care can support the treatment of depression in
people with long-term conditions, but long-term benefits and
costs are unknown.
Aims
To explore the long-term (24-month) effectiveness and cost-
effectiveness of collaborative care in people with mental–phys-
ical multimorbidity.
Method
A cluster randomised trial compared collaborative care (inte-
grated physical and mental healthcare) with usual care for
depression alongside diabetes and/or coronary heart disease.
Depression symptoms were measured by the symptom check-
list-depression scale (SCL-D13). The economic evaluation was
from the perspective of the English National Health Service.
Results
191 participants were allocated to collaborative care and 196 to
usual care. At 24 months, the mean SCL-D13 score was 0.27
(95% CI, −0.48 to −0.06) lower in the collaborative care group
alongside a gain of 0.14 (95% CI, 0.06-0.21) quality-adjusted life-
years (QALYs). The cost per QALY gained was £13 069.
Conclusions
In the long term, collaborative care reduces depression and is
potentially cost-effective at internationally accepted willingness-
to-pay thresholds.
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Relevance statement
Collaborative care integrates physical and mental healthcare. It is
more effective than usual care for managing depression over the
long term in people with coexisting mental and physical health con-
ditions (mental–physical multimorbidity). This is the first long-
term evaluation of collaborative care for managing mental–physical
multimorbidity in a UK setting. Additionally, collaborative care is
good value for money over the long term and has the potential to
deliver important health gains at levels generally considered to be
cost-effective.
Introduction
Multimorbidity refers to the presence of two or more long-term
conditions, which can include combinations of physical and
mental symptoms. Multimorbidity is a critical burden on health
systems, associated with increased mortality, reduced quality of
life and increased use of unscheduled care.1,2 The greatest reduc-
tions in quality of life are experienced by those with mental–phys-
ical multimorbidity3 which is associated with 45–65% higher costs
of care for long-term conditions.4 Collaborative care is a model of
care for people with co-occurring mental and physical health con-
ditions that recognises the interplay between the two. The most
widely accepted current definition of collaborative care includes
four key criteria: a multi-professional approach to patient care, a
structured management plan, scheduled patient follow-ups and
enhanced inter-professional communication.5 A key element is
the appointment of a care manager who acts as a conduit
between patients and healthcare professionals, and works with
the patient to promote better patient self-care.6 There is some evi-
dence that compared with usual care, collaborative care is more
effective for treating depression and anxiety over the short to
medium term, with or without multimorbid long-term condi-
tions,7 but effectiveness beyond 12 months remains uncertain.
The UK National Institute for Health and Care Excellence
(NICE) concluded that there is currently an absence of clinical
or cost-effectiveness evidence for collaborative care in multimor-
bidity.8 In the context of interventions for long-term health condi-
tions it is especially important to evaluate long-term clinical
effectiveness and cost-effectiveness. This article reports the long-
term (24-month) clinical and cost-effectiveness of collaborative
care for people with depression, in the context of high levels of
multimorbidity, as part of the Collaborative Interventions for
Circulation and Depression (COINCIDE) trial.
Method
Trial design and participants
The COINCIDE trial evaluated the clinical effectiveness of collab-
orative care over a short-term period (4 months); collaborative
care was associated with a significantly greater improvement in
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depression symptoms compared with usual care (effect size: 0.30).9
The study protocol (trial registration number: ISRCTN80309252)
has been published previously.6,10
The evaluation was a two-arm, cluster randomised, controlled
trial in the north-west of England. Participating general practices
held electronic registers of patients with diabetes and/or coronary
heart disease and were assigned a unique identifier. A total of 459
general practices across the north-west of England were invited to
participate and 39 were allocated in a phased approach across the
region (9 in Merseyside, 19 in Greater Manchester and 8 in East
Lancashire); three practices withdrew before participants were
recruited. Designated staff based remotely at the Clinical Trials
Unit of the Christie National Health Service (NHS) Foundation
Trust (Manchester, UK) provided a central randomisation service.
A computerised random number generator was used. The first six
practices recruited were allocated at a ratio of 1:1 at random, to
either the collaborative care or usual care arm. Subsequent practices
were then allocated by minimisation (with a probability weighting
of 0.8),11 based on the Index of Multiple Deprivation and practice
list size. An email confirmation of allocation details was sent to
the trial manager. Research staff were blind to the allocation of
enrolled participants. Details of sample size calculations are
reported in full elsewhere;9 the trial had 79% power to detect an
effect size of 0.4.
Staff from the National Institute for Health’s Mental Health
Research Network searched clinical databases at participating prac-
tices for patients with a record of diabetes and/or coronary heart
disease. Patients who met these eligibility criteria were sent a
postal invitation followed by a reminder letter 3 weeks later; non-
responders to the reminder postal invitation were telephoned.
Patients were screened for depressive symptoms (≥10 on the
nine-item Patient Health Questionnaire; PHQ-9)12 by the research
team over the telephone twice over 2 weeks. Patients who met these
criteria for at least 2 weeks were eligible to participate. We excluded
patients with psychosis, patients with type I or type II bipolar dis-
order, those who were currently experiencing suicidal thoughts,
those in receipt of services for substance misuse and those receiving
psychological therapy for depression from a mental health service.
Full details of the trial design are reported in detail in the published
protocol.6,10
Ethical approval
The National Research Ethics Service Committee North West –
Preston (approval number NRES/11/NW/0742) granted ethical
approval, and research governance approvals were granted by par-
ticipating primary care trusts. Informed consent was obtained in
writing from all participants before data collection.
Interventions
Participants attending general practitioner (GP) practices allocated
to the collaborative care arm received up to eight face-to-face ses-
sions of brief psychological therapy delivered by a case manager
over 3 months.6,10 Case managers were ‘psychological well-being
practitioners’ (PWPs) employed by Improving Access to
Psychological Therapy (IAPT) services, given specific training in
delivering the COINCIDE collaborative care model. The first
session was expected to last for 45 min, during which the PWP iden-
tified links between participants’ mood and management of their
long-term conditions with the aim of formulating a problem state-
ment. Subsequent treatment sessions were scheduled to last for 30–
40 min and participants could choose to engage with behavioural
activation, graded exposure, cognitive restructuring and/or lifestyle
changes. A 10min collaborative meeting (by telephone or in person)
between the participant, PWP and a practice nurse from the
participant’s general practice was scheduled to take place during
treatment session two and eight, to facilitate the integration of
care. These collaborative meetings focused on ensuring that psycho-
logical treatments did not complicate current management, review-
ing patients’ progress, reviewing relevant physical andmental health
outcomes and planning future care.9 The final session also included
education about relapse prevention strategies. PWPs were expected
to liaise with the practice nurse and participants’ GPs about medi-
cation and update on participant progress. Participants attending
general practices allocated to the control arm received treatment
as usual based on the NICE stepped care model, provided by the
participants’ GPs.13 This could include treatment of depression
with medication and/or onward referral to psychological therapy.
If participants in the usual care arm were referred to psychological
therapy provided for by Improving Access to Psychological Therapy
services, they did not receive such care from COINCIDE-trained
PWPs.
Outcomes
The primary outcome was self-reported depression severity on the
13 depression items of the Symptom Check List-90 scale (SCL-
D13; range: 0–4) 24 months after randomisation.14 Data on health-
care utilisation were collected with a bespoke patient questionnaire.
Health status wasmeasured with the EuroQol 5D-5L (EQ-5D-5L).15
All baseline measures were collected face to face by research staff
blind to allocation; self-reported outcome measures at 24 months
were collected by postal questionnaires. Participants who did not
return the 24-month questionnaire were contacted by telephone
and given the opportunity to complete the primary outcome over
the telephone with a researcher blind to allocation.
For economic analyses, we used the UK NHS and personal
social services perspective in line with NICE guidance for economic
evaluations of healthcare interventions.16 The time horizon for the
economic evaluation was 24 months. Data on resource utilisation
were collected at 4 months (covering the period between baseline
and 4 months) and 24 months (covering the period between 4
and 24 months). Therefore, it was not possible to distinguish
which visits occurred in the period between 4 and 12 months and
which occurred between 12 and 24 months. For this reason, costs
associated with healthcare utilisation beyond 12 months were not
discounted. For comparability, outcomes were also not discounted.
Use of healthcare services was collected by asking participants to
report their total number of visits to different healthcare profes-
sionals in these categories: in-patient admission, out-patient, day
patient (non-overnight hospital admission), accident and emer-
gency, and primary/ community care (e.g. GP, nurse, social
worker). Direct costs were also estimated for the intervention.
Data on the resources used to provide the intervention only were col-
lected from activity logs completed by PWPs and practice nurses
who delivered care to participants in the collaborative care arm.
The costs of training PWPs were also included in the primary eco-
nomic analysis. We based PWP costs on NHS Agenda for Change
salary band four (current salary range: £19 217–22 458; US$24
271–28 364; €21 793–25 469) and included employer National
Insurance and pension contributions plus capital, administrative
and managerial costs. We calculated cost per hour using standard
working time assumptions,17 weighted to account for time spent
on non-patient-facing activities. For each type of resource, the cost
was estimated as the quantity of that resource or service used multi-
plied by nationally applicable unit costs.17,18 All direct costs are
reported in British pounds (£) and inflated to 2015–2016 prices by
the Hospital and Community Health Services Index.17
The primary measure of cost-effectiveness was cost per quality-
adjusted life-year (QALY).16 Utility values were derived at each time
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point from the EQ-5D-5L and associated utility tariffs for the UK,
generated from a series of time trade-off and discrete choice experi-
ments.19 The EQ-5D-3L crosswalk method20 was used to estimate
utility values as a sensitivity analysis. A mean utility value was cal-
culated for each set of two time points (baseline to 4 months; 4–24
months). The mean utility value and length of the respective time
period (e.g. a utility value of 1 is equivalent to 0.5 QALYs if
accrued over 6 months, or 1 QALY if accrued over 12 months)
was used to generate two QALY values (one for each time
period), which were combined to estimate the total QALYs
during the whole follow-up period.
Statistical analysis
We used an intention-to-treat approach for all clinical and cost-
effectiveness analyses as per the original data analysis plan shared
with the Data Monitoring and Ethics Committee. All analyses
were conducted with Stata (Release 13). The trial originally had
80% power (two-sided α = 0.05) to detect a difference between
groups on the primary outcome at follow-up, equivalent to a stan-
dardised effect size of 0.4, for which we required 15 practices per
arm and 15 patients per practice (n = 450), allowing for 20% attri-
tion and an intra-practice correlation of 0.06. Average recruitment
in the first 11 practices was <15 patients per practice. We therefore
increased the total number of clusters from 30 to 36, with a target of
10 patients per practice, giving 79% power to detect an effect of 0.4
under the same assumptions. The revised target sample was there-
fore 360 patients.10
To compare the change in depression scores between partici-
pants randomised to collaborative care or usual care, multiple linear
regression with robust standard errors was used; this accounted for
the clustering of patients within practices. The following baseline
characteristics were controlled for: depression score, age, gender,
area deprivation (based on residential postcode), level of limitation
of daily activities at baseline, use of antidepressants or antianxiety
drugs (currently, previously or never), GP practice list size and
GP practice area deprivation (the latter two as ‘design factors’).
Multiple imputation was used to estimate missing scale scores and
other data values at both baseline and follow-up. Thirty imputed
data-sets were generated with chained equations, including covari-
ates as listed above. As part of the imputation model, missing SCL-
D13 values were restricted to between 0 and 4, in line with the
possible questionnaire responses. To assess sensitivity of the
results to multiple imputation, we conducted secondary analyses
on complete cases, first with the same covariates as the main ana-
lysis and second with only baseline depression score included as a
covariate. A further post hoc sensitivity analysis was conducted
without restricting the range of imputed SCL-D13 values.
Economic analysis
The base–case (primary) economic analysis calculated incremental
cost-effectiveness ratios (ICERs); accordingly, no parametric statis-
tical tests of differences in mean costs or outcomes were conducted.
Net QALYs (collaborative care versus usual care) were estimated by
a linear regression model, and net costs were estimated by a general-
ised linear regression model with a log link and gamma family to
allow for the non-normal distribution of costs. Regression models
were adjusted for baseline variables identified through stepwise
regression, using the following measures: World Health Organization
Quality of Life Instrument,21 Generalised Anxiety Disorder seven-
item Scale,22 PHQ-9, Self-Efficacy Questionnaire,23 Health
Education Impact Questionnaire,24 Sheehan Disability Scale,25
employment status and mobility (EQ-5D-5L). Robust standard
errors were used to account for the clustering of patients within
practices. The estimates of incremental costs and outcomes from
the regression were bootstrapped to simulate either 2000 or
10 000 pairs of net cost and net outcomes for a cost-effectiveness
acceptability analysis, as recommended by NICE for health technol-
ogy appraisals.16
Missing data on costs and EQ-5D-5L utility scores were
imputed five times with a chained-equation procedure. Costs were
imputed by category and utility by individual EQ-5D-5L domain
rather than as totals, so that all available data were used to inform
the imputed values. The pattern of available cost and utility data
across the different assessments are summarised in supplementary
Table 1, available at https://doi.org/10.1192/bjp.2018.70. For the
24-month assessment, 69% of the original sample had a cost
recorded for at least one category of healthcare and 69% had
responded to at least one item on the EQ-5D-5L. All available (com-
plete and partial) cost and outcome data for a particular participant
was used to impute missing data. The number of imputed data-sets
was chosen for pragmatic reasons: it was felt that this represented a
balance between robustness and the computational burden of con-
ducting the bootstrapping procedure on imputed data.
Sensitivity analyses assessed the effect of design and analysis
choices on the cost-effectiveness of collaborative care. These were
an alternative method for utility/QALY estimation (crosswalk
approach),20 a complete case analysis, an alternative measure of
health benefit (proportion of participants showing a ‘response’ –
40% improvement from baseline in SCL-D13 score),26 excluding
the cost of training the PWPs and number of bootstrap simulations.
Results
19 practices were randomised to collaborative care and 20 to usual
care. We identified 387 patients with depression and heart disease
and/or diabetes and invited them to a baseline assessment.
Follow-up data on 350 (90% of original sample) participants were
collected at 4 months between 18 November 2012 and 4 October
2013, and follow-up data on 272 participants (71% of original
sample) were collected at 24 months between 18 May 2014 and 4
June 2015 (see supplementary material for the Consolidated
Standards of Reporting Trials (CONSORT) diagram).
Characteristics of participating practices and participants are
reported in Table 1. The majority (63%) of participants at baseline
met criteria for moderately severe or severe depression, and 75% of
participants met criteria for anxiety. Participants reported a mean of
6.2 (s.d. = 3.2) long-term conditions in addition to either diabetes or
coronary heart disease; 15% of participants had a diagnosis of both
diabetes and coronary heart disease. The mean age was 58.5 years
and 38% of participants were female. Around half (54%; n = 211)
of participants lived in areas ranked as highly deprived (index of
multiple deprivation score ≥30). A total of 25% of participants
were in paid employment. Half of participants were prescribed anti-
depressant or antianxiety medication at baseline. Full details about
the delivery of the intervention have been previously reported.9
For the primary outcomemeasure, depression scores were avail-
able at 24 months for 62% of participants allocated to the collabora-
tive care arm and 74% allocated to usual care. The primary measure
of health benefit for the economic evaluation was completed by 61%
of collaborative care participants and 68% of usual care participants
at 24 months. Across the categories of healthcare utilisation,
70–83% of participants had complete data at 4 months and 64–
68% at 24 months. However, when combined into a total cost,
34% of the collaborative care group and 40% of the usual care had
data for all of the categories at both time points. An additional
summary of available cost and utility data is reported in supplemen-
tary Table 2.
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The unadjusted difference in mean SCL-D13 scores between
baseline and first follow-up showed an improvement in both
groups (4-month improvement: collaborative care 0.61; usual care
0.31) (Table 2 and Figure 1a). When compared with baseline
values, 24-month depression scores were again lower in both
groups, with the greater improvement maintained in the collabora-
tive care arm (24-month improvement: collaborative care 0.84;
usual care 0.55).
After adjustment for covariates, the mean SCL-D13 score at
24-month follow-up was 0.27 points lower (95% CI, −0.48 to
−0.06; P = 0.014) in participants who received collaborative care com-
pared with those who received usual care. This difference is equal to a
standardised mean difference of −0.35 (95% CI, −0.62 to −0.05),
using the baseline pooled s.d. for SCL-D13. Collaborative care was
also found to be significantly more effective than usual care at 24
months in all sensitivity analyses, although there was very little differ-
ence in the estimated coefficients between models (Table 2).
Cost-effectiveness
The mean cost of the collaborative care intervention was £321,
including a training cost of £130 per participant (total training
costs divided by the total number of participants randomised to col-
laborative care irrespective of number of PWP sessions attended).
For participants with complete cost data at all time points, the
mean cost across all categories of healthcare was higher among
those randomised to collaborative care; the cost of healthcare
resources used was higher across all categories except day patient
hospital visits and emergency department visits (see supplementary
Table 3).
Unadjusted mean health state index scores show that the usual
care group worsened overall between baseline and 24 months
(Figure 1b; also see supplementary Table 3). The collaborative
care group improved between baseline and first follow-up, which
was sustained at the 24-month follow-up.
Regression analysis onmultiple imputed data-sets also showed a
higher net cost associated with collaborative care (compared with
usual care); £1777 (95% CI, −£320 to £3875) over 24 months,
although this difference is not statistically significant. Participants
receiving collaborative care accrued significantly more QALYs
over 24 months than those receiving usual care (0.136; 95% CI,
0.061 to 0.212). The bootstrapped estimates of net costs and
QALYs are shown on a cost-effectiveness plane in Figure 1c. The
simulations are predominantly located in the upper-right quadrant
of the plane, indicating a net cost associated with collaborative care
alongside a net health benefit (QALY gain). The points on the plane
show more vertical than horizontal spread, illustrating that there is
greater uncertainty around the estimated net cost than the estimated
net benefit.
The cost per additional QALY gained from collaborative care
(compared with usual care) is £13 069. The probability of collabora-
tive care being cost-effective is 0.75 if decision makers are willing to
pay £20 000 to gain one QALY. If decision makers are willing to pay
£30 000 to gain one QALY, the probability that collaborative care is
more cost-effective than usual care is 0.92. This is shown in the cost-
effectiveness acceptability curve in Figure 1d.
Table 2 Mean depression scores (SCL-D13) at all time points and change in depression scores between baseline and 24 months
Collaborative care Usual care
n Mean (s.d.) n Mean (s.d.)
Baseline 191 2.364 (0.696) 196 2.330 (0.822)
4 months 170 1.756 (0.938) 180 2.020 (0.935)
24 months 119 1.527 (0.945) 145 1.785 (1.034)
Attrition rate (baseline to 24 months) 37.7% 26.0%
Adjusteda difference in means Effect size
(95% CI) (95% CI)
Primary analysis
Imputed data (n = 387) −0.269 (−0.476 to −0.061) −0.353 (−0.624 to −0.047)
Sensitivity analysis
Complete cases (n = 245) −0.264 (−0.450 to −0.078) −0.346 (−0.454 to −0.102)
Complete cases (adjusted for baseline SCL-D13 score only) (n = 264) −0.260 (−0.416 to −0.104) −0.341 (−0.546 to −0.136)
Imputed data, regression model not constrained to possible value range (0–4)
for mean SCL-D13 (n = 387)
−0.260 (−0.416 to −0.104) −0.341 (−0.546 to −0.136)
SCL-D13, Symptom Checklist-13 Depression Scale.
a. Adjusted for all following covariates unless otherwise indicated: age, gender, socioeconomic deprivation, limitation of daily activities owing to comorbidities, use of antidepressants or
antianxiety drugs and general practitioner practice characteristics.
Table 1 Baseline characteristics of COINCIDE trial practices and
participants
Collaborative care
(n = 191)
Usual care
(n = 196)
n (%) n (%)
Practice area
Affluent 49 (26) 43 (22)
Moderately deprived 80 (42) 90 (46)
Heavily deprived 62 (33) 63 (32)
Practice size
Small (<4500) 60 (31) 49 (25)
Medium (4500 to 7500) 61 (32) 41 (21)
Large (>7500) 70 (37) 106 (54)
Participant characteristics
Age in yearsa 57.9 (12.0) 59.2 (11.4)
Gender female 78 (41) 69 (35)
Ethnicity White 162 (85) 167 (85)
QOF register diabetes 106 (56) 101 (51)
QOF register CHD 56 (29) 66 (34)
QOF register diabetes and CHD 29 (15) 29 (15)
Mean (s.d.) Mean (s.d.)
Deprivation IMD score (low score
indicates high deprivation)
36.6 (21.3) 34.4 (18.5)
Number of long-term physical
conditionsb
6.0 (3.2) 6.5 (3.1)
PHQ-9 total depression score (0–27) 16.4 (4.2) 16.5 (4.1)
GAD-7 total anxiety score (0–21) 12.3 (5.1) 11.9 (5.3)
COINCIDE, Collaborative Interventions for Circulation and Depression; QOF, quality
outcomes framework; CHD, coronary heart disease; IMD, Index of Multiple Deprivation;
PHQ-9, Patient Health Questionnaire 9; GAD-7, Generalised Anxiety Disorder seven-item
Scale.
a. Mean (s.d.).
b. Excluding diabetes and CHD.
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There was little difference in the 95% confidence intervals
generated from non-parametric bootstrapping 2000 or 10 000
pairs of net costs and benefits, and no effect on the cost-effective-
ness recommendation (Table 3). When the crosswalk method was
used for estimating utility values from the EQ-5D-5L, the net
QALYs were slightly lower than for the time trade-off approach
(0.118 v. 0.136), resulting in a slightly higher ICER (£15 063/
QALY v. £13 069/QALY). When only participants with complete
cost and QALY data were included in the analysis, net costs were
higher and net QALYs lower than the primary (base–case) ana-
lysis. This resulted in an ICER of £38 032 per QALY at which col-
laborative care would be unlikely to be more cost-effective than
usual care (probability 0.42 at a willingness-to-pay threshold of
£30 000). When the measure of health benefit was the number
of people showing a clinical response in terms of depression
symptoms (40% reduction in total SCL-D13 score26 between
baseline and 24 months), there were 50 more ‘responders’ in
the collaborative care group. Alongside the net cost of £1777,
the cost per each additional responder was estimated to be £36.
There is no guidance on how much decision makers are willing
to pay for a treatment response, therefore it is not meaningful
to calculate a probability of cost-effectiveness in terms of this
outcome measure.
Discussion
Collaborative care for depression in the context of multimorbidity is
clinically and cost-effective over the long term. Not only were the
treatment effects of collaborative care maintained over 24 months,
but they marginally exceeded those reported at 4 months (standar-
dised mean difference 0.35 v. 0.30). Collaborative care was also asso-
ciated with superior QALY gains compared with usual care (i.e.
when both mental and physical domains of health are considered)
in this context.
This is the first long-term evaluation of collaborative care for
managing mental–physical multimorbidity in a UK primary care
setting. The net QALY gain observed in the COINCIDE trial at
24 months was greater than that observed in a previous economic
evaluation of collaborative care in UK primary care.27 We previ-
ously reported results of an economic model estimating the long-
term cost-effectiveness of collaborative care, based on data observed
at 4 months in the COINCIDE trial.28 The net QALY gain observed
here from 24-month trial data (0.14) was similar to the modelled
scenario, which assumed that the benefit of collaborative care
accrued at 4 months would be maintained at the same level over
24 months (net QALY gain 0.15). Our findings here support this
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Fig. 1 Summary of clinical effectiveness and cost-effectiveness results.
(a) Mean Symptom Checklist-13 Depression Scale (SCL-D13) scores during follow-up by treatment group, unadjusted values (solid line
represents collaborative care; dashed line represents usual care). (b) Mean health state index (EuroQol 5D-5L) scores during follow-up by
treatment group, unadjusted values (solid line represents collaborative care; dashed line represents usual care). (c) Cost-effectiveness plane
(primary analysis): distribution of 10 000 bootstrapped simulations of net cost and net quality-adjusted life-year (QALY) pairs (large white square
indicates point estimate for incremental cost-effectiveness ratio). (d) Cost-effectiveness acceptability curve (primary analysis).
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assumption; the mean utility values were similar at 4 and 24 months
in the collaborative care group, although the ICER estimated from
the model was somewhat lower than for the 24-month trial data
(£3468/QALY (model) v. £13 069/QALY (trial)).
An important difference between the economic model and
observed data is the estimated net cost. Net costs were notably
higher using data observed within-trial, meaning that the additional
healthcare resources used by participants randomised to collabora-
tive care was greater than expected. Participants in the collaborative
care arm used almost £1800 more of healthcare resources over 24
months (crudely, £900 over 12 months) than those receiving
usual care. By comparison, in the Clinical and Cost Effectiveness
of Collaborative Care for Depression in UK Primary Care Trial
(CADET) the cost of healthcare resources over 12 months were
almost identical between usual and collaborative care treatment
groups.27 The unexpectedly high resource use might partly be
explained by participants in the collaborative care arm reporting
improved navigation of health services and more engagement
with health-directed behaviours, as evidenced by higher ratings on
the Health Education Impact Questionnaire, compared with usual
care.9 This may have led to increased but more appropriate use of
healthcare resources and thereby improved levels of both physical
and mental functioning.
Strengths and limitations
The COINCIDE trial was a large, pragmatic trial conducted across a
wide geographical area in the north-west of England that included a
population with high levels of multimorbidity, disability and depriv-
ation. This makes it particularly relevant to the management of
mental–physical multimorbidity, which is more prevalent in
younger adults from deprived regions.29 Cluster randomisation
and analytic approaches for imputing data and adjusting for base-
line characteristics offered greater opportunities to minimise bias
and confounding. Additionally, the 24-month follow-up period is
the longest time horizon used in an integrated economic and effect-
iveness evaluation of collaborative care outside the USA.
Our economic analysis conforms to the high standards of analysis
and reporting expected of cost-effectiveness analyses of health inter-
ventions (see supplementary material for the Consolidated Health
Economic Evaluation Reporting Standards checklist). However,
data was not captured at baseline regarding use of health services
before the intervention so it is not possible to determine or adjust
for any underlying differences between the treatment groups.
Although multiple imputation of missing data reduced the
potential for bias associated with missing data, the robustness of
any imputation method declines as the level of missing data
increases, reducing the validity and reliability of the analyses.
Data from baseline and 24 months only were included in the clinical
effectiveness analysis, and there was little difference in the change in
depression score or effect size between the complete case analysis
and the analysis after multiple imputation. The attrition rate was
higher among participants in the collaborative care group (37.7%)
compared with usual care (26.0%). We have explored key character-
istics between participants with and without complete data (results
not shown) and found only that in the usual care group, the mean
age was higher (66 years) for those with incomplete data for the
primary outcome measure than those with complete data (59
years). There were no other differences. Age was adjusted for in
all analyses and included in the multiple imputation model, there-
fore this is unlikely to have unduly biased our results.
The economic evaluation included cost and utility data from
baseline, 4 months and 24 months, and so there was greater scope
for data to be missing. The proportion of participants with complete
cost or utility data for all three time points (baseline, 4 months and 24
months) was lower than at the final time point (24 months) alone,
suggesting that missing data items rather than loss to follow-up con-
tributed to the level of missing data. Almost 70% of participants had
complete cost or utility data; however, the proportion of participants
with data for both was lower. As described in the Methods section, all
available data were used to inform the imputed values and the role of
multiple imputation can be thought of as filling in the blanks. A post
hoc comparison of the characteristics of the participants with com-
plete/incomplete economic data showed that only ethnicity was
Table 3 Net costs and QALYs, ICER and probability collaborative care is cost-effective, using primary and sensitivity analyses, adjusted for baseline
covariates, bootstrapped and imputed data (unless otherwise stated)
Net cost (95% CI) Net QALY (95% CI) ICER (£/QALY) Probability collaborative care is
cost-effective versus usual care
if WTPT =
£15 000/
QALY
£20 000/
QALY
£30 000/
QALY
Primary analysis
Multiple imputation (n = 387), 10 000 bootstrap
simulations
1777 (−320 to 3875) 0.136 (0.061–0.212) £13 069/QALY 0.58 0.75 0.92
Multiple imputation (n = 387), 2000 bootstrap
simulations
1777 (−313 to 3867) 0.136 (0.061–0.212) £13 069/QALY 0.57 0.75 0.92
Sensitivity analyses (2000 bootstrap simulations)
QALYs estimated with crosswalk methodology20 1777 (−313 to 3867) 0.118 (0.001–0.235) £15 063/QALY 0.49 0.63 0.78
No imputation (complete cases, n = 130) 3347 (−1119 to 7813) 0.088 (−0.060 to 0.237) £38 032/QALY 0.21 0.28 0.42
Excluding PWP training costs 1632 (−457 to 3722) 0.136 (0.061–0.212) £12 002/QALY 0.62 0.78 0.93
Number of responders
(95% CI)
Cost per additional
person responding
to treatment
Health benefit: ‘response’ on SCL-13 (40%
improvement from baseline)21
1777 (−320 to 3875) Usual care: 35 (25–45),
collaborative care:
85 (72–98),
difference: 50
£36a – – –
Covariates costs: baseline mobility (EuroQol-5D), general practitioner practice (cluster). Covariates QALYs: baseline scores for World Health Organization Quality of Life Instrument,
Generalised Anxiety Disorder seven-item Scale, Patient Health Questionnaire 9, Self-Efficacy Questionnaire, Health Education Impact Questionnaire, Sheehan Disability Scale, employment
status and general practitioner practice (cluster).
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; WTPT, willingness-to-pay threshold; PWP, psychological well-being practitioner; SCL-D13, Symptom Checklist-13
Depression Scale.
a. Net cost (£1777) divided by the number of additional responders (50).
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significantly different: there was a higher proportion of black and
minority ethnic participants with complete data than incomplete
data (see supplementary Table 2). This was surprising because for
the participants who did not return the 24-month postal question-
naire, only English speakers were able to complete it over the tele-
phone (because of limited resources). The cost-effectiveness results
were somewhat sensitive to missing data. The direction of the effect
on costs and QALYs were the same, but the cost to gain one QALY
was higher in the complete case analysis.
Data on depression symptoms (SCL-D13), health status (EQ-
5D-5L) and healthcare resource utilisation were self-reported by
participants. Although pragmatic, self-reported methods are poten-
tially prone to recall bias over a long-term follow-up. This is espe-
cially true in relation to capturing healthcare utilisation,
particularly among those who use a large number of different
healthcare services. However, use of costly services (e.g. an in-
patient admission or major surgery) are notable events and likely
to be recalled even over a long period.30,31 Furthermore, the inter-
vention in this trial was not expected to affect recall of healthcare
utilisation. Although total costs may be an underestimation, this
is expected to be to the same extent in both groups and unlikely
to influence the net cost. The second follow-up (at 24 months)
had not been funded at the time of writing the original protocol
for the COINCIDE trial, and so participants were only approached
for second follow-up after the original study period had ended. If it
had been possible to inform participants about the second follow-up
earlier, the attrition rate may have been lower. However, a 68%
retention rate over 24 months for the primary outcome measure
is acceptable and, as described above, multiple imputation was
used to minimise the effect of missing data. Additionally, we were
only resourced to collect long-term follow-up data for the
primary and economic outcomes, making it impossible to address
questions about the long-term effect of the intervention on second-
ary outcomes evaluated in our short-term analysis.9
Implications
A strong case for routinely using collaborative care as a framework
of care for depression was made by the CADET trial.27,32 We have
shown that collaborative care is as effective in people with long-term
conditions as it is in people with depression alone.7 However,
current NICE guidance about the management of multimorbidity
has excluded evidence from interventions that primarily target
depression. The rationale for this was that any benefits for physical
health may be an indirect effect of improvements in mood.
Although the COINCIDE trial was designed as a depression inter-
vention, it has been identified as an approach that can effectively
integrate the mental and physical healthcare of people with multi-
morbidity in primary care.33 In the COINCIDE trial, collaborative
care improved both depression and physical functioning in people
with multimorbidity. Furthermore, collaborative care is also likely
to be cost-effective over the long term. These findings address an
evidence gap identified by NICE when developing their guideline/
recommendations regarding the management of multimorbidity.8
In conclusion, the need for cost-effective interventions for mul-
timorbidity is of paramount importance in high-, middle-, and low-
income regions faced with the burden of managing ageing and/or
deprived populations with complex health needs. Despite the limita-
tions of this analysis, it can be concluded that collaborative care is
clinically effective (with a moderate effect size) and cost-effective
over the long term, as a treatment for people with depression in
the context of multimorbidity. In addition to existing evidence, find-
ings from the COINCIDE trial send a strong signal to clinicians and
commissioners in primary care that collaborative care merits
implementation to manage the effect of mental–physical multimor-
bidity over the long term.
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